1. Home
  2. ZYME vs WD Comparison

ZYME vs WD Comparison

Compare ZYME & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$22.16

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Walker & Dunlop Inc

WD

Walker & Dunlop Inc

HOLD

Current Price

$63.18

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZYME
WD
Founded
2003
1937
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
2017
2010

Fundamental Metrics

Financial Performance
Metric
ZYME
WD
Price
$22.16
$63.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
3
Target Price
$32.75
$83.33
AVG Volume (30 Days)
843.3K
219.5K
Earning Date
03-04-2026
02-26-2026
Dividend Yield
N/A
4.15%
EPS Growth
N/A
20.18
EPS
N/A
3.37
Revenue
$134,481,000.00
$1,160,070,000.00
Revenue This Year
$63.10
$21.20
Revenue Next Year
$93.26
$10.20
P/E Ratio
N/A
$19.16
Revenue Growth
116.21
17.65
52 Week Low
$9.03
$58.60
52 Week High
$28.49
$96.00

Technical Indicators

Market Signals
Indicator
ZYME
WD
Relative Strength Index (RSI) 38.08 47.37
Support Level $22.00 $60.45
Resistance Level $23.79 $65.16
Average True Range (ATR) 0.88 2.00
MACD -0.04 -0.13
Stochastic Oscillator 3.90 34.05

Price Performance

Historical Comparison
ZYME
WD

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About WD Walker & Dunlop Inc

Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.

Share on Social Networks: